Takayuki Yoshino

Takayuki Yoshino

Auto-generated profile, based on publicly available information

Takayuki Yoshino

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DKDaisuke Kotani
Daisuke Kotani
EOEIJI OKI
EIJI OKI
YNYoshiaki Nakamura
Yoshiaki Nakamura
HYHiroki Yukami
Hiroki Yukami
SMSaori Mishima
Saori Mishima
TYTakayuki Yoshino
Takayuki Yoshino
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II–IV resectable CRC (n = 1,039). In this cohort, with a median follow-up of 16.74 months (range 0.49–24.83 months), postsurgical ctDNA positivity (at 4 weeks after surgery) was associated with higher recurrence risk (hazard ratio (HR) 10.0, P < 0.0001) and was the most significant prognostic factor associated with recurrence risk in patients with stage II or III CRC (HR 10.82, P < 0.001). Furthermore, postsurgical ctDNA positivity identified patients with stage II or III CRC who derived benefit from ACT (HR 6.59, P < 0.0001). The results of our study, a large and comprehensive prospective analysis of ctDNA in resectable CRC, support the use of ctDNA testing to identify patients who are at increased risk of recurrence and are likely to benefit from ACT.

16 November 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
TYT. Yoshino
T. Yoshino
DAD. Arnold
D. Arnold
HTH. Taniguchi
H. Taniguchi
GPG. Pentheroudakis
G. Pentheroudakis
KYK. Yamazaki
K. Yamazaki
JDJ.-Y. Douillard
J.-Y. Douillard
The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

1 June 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
SSSalvatore Siena
Salvatore Siena
MBMaria Di Bartolomeo
Maria Di Bartolomeo
KRKanwal Raghav
Kanwal Raghav
TMToshiki Masuishi
Toshiki Masuishi
FLFotios Loupakis
Fotios Loupakis
TYTakayuki Yoshino
Takayuki Yoshino

5 October 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YNYoshiaki Nakamura
Yoshiaki Nakamura
HTHiroya Taniguchi
Hiroya Taniguchi
MIMasafumi Ikeda
Masafumi Ikeda
HBHideaki Bando
Hideaki Bando
KKKen Kato
Ken Kato
TYTakayuki Yoshino
Takayuki Yoshino

16 September 2024 in Nature Medicine
Verified
Journal Article
Open access
YNYoshiaki Nakamura
Yoshiaki Nakamura
JWJun Watanabe
Jun Watanabe
NANaoya Akazawa
Naoya Akazawa
KHKeiji Hirata
Keiji Hirata
KKKozo Kataoka
Kozo Kataoka
EOEIJI OKI
EIJI OKI
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated analysis with a 23-month median follow-up, including 2,240 patients with stage II-III colon cancer or stage IV CRC, reinforces the prognostic value of ctDNA positivity during the MRD window with significantly inferior disease-free survival (DFS; hazard ratio (HR): 11.99, P < 0.0001) and overall survival (OS; HR: 9.68, P < 0.0001). In patients who experienced recurrence, ctDNA positivity correlated with shorter OS (HR: 2.71, P < 0.0001). The significantly shorter DFS in MRD-positive patients was consistent across actionable biomarker subsets. Sustained ctDNA clearance in response to ACT was an indicator of favorable DFS and OS compared to transient clearance (24-month DFS: 89.0% versus 3.3%; 24-month OS: 100.0% versus 82.3%). True spontaneous clearance rate with no clinical recurrence was 1.9% (2/105). Overall, our findings provide evidence for the utility of ctDNA monitoring for post-resection recurrence and mortality risk stratification that could be used for guiding adjuvant therapy.

1 October 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
TYTakayuki Yoshino
Takayuki Yoshino
NMNobuyuki Mizunuma
Nobuyuki Mizunuma
KYKentaro Yamazaki
Kentaro Yamazaki
TNTomohiro Nishina
Tomohiro Nishina
YKYoshito Komatsu
Yoshito Komatsu
AOAtsushi Ohtsu
Atsushi Ohtsu